Contineum Therapeutics Appoints New CMO, CSO, and Directors
Ticker: CTNM · Form: 8-K · Filed: Jun 24, 2024 · CIK: 1855175
| Field | Detail |
|---|---|
| Company | Contineum Therapeutics, Inc. (CTNM) |
| Form Type | 8-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, executive-appointment
TL;DR
Contineum Therapeutics beefs up leadership with new CMO, CSO, and board members.
AI Summary
Contineum Therapeutics, Inc. announced on June 21, 2024, the appointment of Dr. Jonathan Leipsic as Chief Medical Officer and Dr. David E. Cohen as Chief Scientific Officer. The company also reported the election of Ms. Sarah E. Kelly and Mr. David M. R. Johnson to its Board of Directors. These changes are effective immediately.
Why It Matters
The appointment of experienced medical and scientific officers, along with new board members, signals a strategic move by Contineum Therapeutics to bolster its leadership and potentially advance its drug development pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding strategic direction and operational execution, though they can also signal positive future developments.
Key Players & Entities
- Contineum Therapeutics, Inc. (company) — Registrant
- Jonathan Leipsic (person) — Appointed Chief Medical Officer
- David E. Cohen (person) — Appointed Chief Scientific Officer
- Sarah E. Kelly (person) — Elected to Board of Directors
- David M. R. Johnson (person) — Elected to Board of Directors
- June 21, 2024 (date) — Effective date of appointments and elections
FAQ
Who has been appointed as the new Chief Medical Officer at Contineum Therapeutics?
Dr. Jonathan Leipsic has been appointed as the new Chief Medical Officer.
What is the name of the new Chief Scientific Officer?
Dr. David E. Cohen has been appointed as the new Chief Scientific Officer.
Who were the individuals elected to the Board of Directors?
Ms. Sarah E. Kelly and Mr. David M. R. Johnson were elected to the Board of Directors.
When were these appointments and elections effective?
The appointments and elections are effective as of June 21, 2024.
What was Contineum Therapeutics formerly known as?
Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc.
Filing Stats: 868 words · 3 min read · ~3 pages · Grade level 9.8 · Accepted 2024-06-24 16:11:11
Key Financial Figures
- $0.001 — tered Class A Common Stock , par value $0.001 per share CTNM The Nasdaq Global Mar
Filing Documents
- cont20240611_8k.htm (8-K) — 32KB
- 0001437749-24-021083.txt ( ) — 167KB
- noticker-20240621.xsd (EX-101.SCH) — 3KB
- noticker-20240621_def.xml (EX-101.DEF) — 12KB
- noticker-20240621_lab.xml (EX-101.LAB) — 15KB
- noticker-20240621_pre.xml (EX-101.PRE) — 12KB
- cont20240611_8k_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 10.1 Form of Indemnity Agreement (incorporated by reference to Exhibit 10.1 to the Registrant ' s Amended Registration Statement on Form S-1/A (File No. 333-278003) filed with the Securities and Exchange Commission on April 1, 2024). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 24, 2024 CONTINEUM THERAPEUTICS, INC. By: /s/ Peter Slover Peter Slover Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)